Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 2/20 | 0.59 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342556 | 1.00 | CYP1A2 (0.68) | CYP1A2TGM2CTSKCTSBCTSS | |
| SCHEMBL9595102 | 0.84 | CYP1A2 (0.78) | CYP1A2CTSKCTSBCTSSCTSL | |
| SCHEMBL12126850 | 0.82 | CYP1A2 (0.58) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL1311568 | 0.81 | CYP1A2 (0.58) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL1665353 | 0.81 | CYP1A2 (0.57) | CYP1A2 | |
| SCHEMBL13578646 | 0.78 | CYP1A2 (0.51) | CYP1A2TGM2 | |
| SCHEMBL13578626 | 0.78 | CYP1A2 (0.51) | CYP1A2TGM2 | |
| SCHEMBL6316867 | 0.78 | CYP1A2 (0.59) | CYP1A2 | |
| SCHEMBL12115444 | 0.77 | CTSL (0.61) | CTSKCTSBCTSSCTSL | |
| SCHEMBL1091157 | 0.77 | TGM2 (0.93) | TGM2CTSKCTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | CYP1A2 1812/4885TGM2 2425/4885CTSK 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.